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cipients are lacking.
Methods: We evaluated characteristics, diagnostic results,
management and outcomes of all inﬂuenza A infections
(pandemic H1N1 versus SFlu) and determined the risk fac-
tors associated with pneumonia and all-cause mortality in
HM patient and HSCT recipients at MD Anderson Cancer
Center (MDACC) from April 2009 to July 2013.
Results: A total of 259 patients were identiﬁed, including 134
(52%) HMpatients and 125 (48%) HSCT recipients. Majority of
patients (242, 93%) were adults, males (147, 57%) with un-
derlying diseases in remission (160, 64%). About half of pa-
tients required hospitalization for outcomes including
pneumonia 28% (72 pts) and death 6% (16 pts). Majority of
patients (214, 83%) received antiviral therapy within a me-
dian of 3 days (range, 0d e 28d) after onset of ﬁrst symptom.
Compared to HCT recipients, a signiﬁcantly higher percent-
age of HM pts were in active stages of cancer with severe
neutropenia (26, 20%) and severe lymphopenia (25, 19%) and
required hospitalization (76, 57%). Multivariable logistic
regression analysis identiﬁed hematologic malignancy (AOR:
2.5 (95% CI: 1.2, 5.28), decreased albumin (AOR: 2.2 (95% CI:
1.0, 4.64), and delay in initiation of antiviral therapy (AOR:
1.3 (95% CI: 1.12, 1.47) as signiﬁcant risk factors for devel-
opment of pneumonia (P¼ 0.05), after adjusting for the virus
strain. Interestingly, H1N1 infections were more prevalent in
Hispanic population (26, 31%) and requiredmore mechanical
ventilation (9, 11%) compared to SFlu, but no signiﬁcant dif-
ferences were observed with respect to pneumonia or mor-
tality between these two viruses.
Conclusions: Inﬂuenza remains a signiﬁcant cause of
morbidity and mortality in HM patients and HSCT recipients.
Compared to HCT recipients, HM patients weremore likely to
progress to pneumonia, probably owing to active cancer
stage and pancytopenia. H1N1 patients did not have higher
mortality rate compared to SFlu in either of the groups. Early
antiviral therapy remains crucial in preventing morbidity in
this population.395
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Background: Thalassemia syndromes are very prevalent in
many parts of the world including Asia. Allogeneic hemato-
poietic cell transplantation (HCT) is the only curative therapy
accepted worldwide.
Objectives: To assess outcomes of HCT for thalassemias and
hemoglobinopathies in single medical center in Thailand.
Methods: Case series study for thalassemia and hemoglo-
binopathy patients undergoing HCT at Bangkok Hospital
Medical Center from February 2009 thru October 2013.
Results: Therewere totally 14 patients. 10 cases were Thais, 1
was French-Thai, 1 was Bangladeshi, 1 was Lao, and 1 was
Omani who had sickle cell disease (SCD). 12 cases were
diagnosed as beta-thalassemia/hemoglobin E diseases, 1 as
transfusion-dependent alpha-thalassemia, and 1 as SCD.
Among 14 HCTs, 9 patients underwent bone marrow trans-
plant (BMT), 4 patients underwent umbilical cord blood
transplant (CBT), and 1 patient underwent combined cordblood and marrow transplantation. All 14 related donors
were fully-HLA-matched, 4 had normal typing, 9 had thal-
assemia trait, and 1 had sickle cell trait. Male to female pa-
tients ratiowere 11:3. Patients’ ages at transplant varied from
2 years to 15 years 11 months with median of 4 years 10
months. Patient’s body weight varied from 11.1 to 50 kilo-
gram (median 17.2 kilogram). According to Pesaro classiﬁ-
cation, among 13 thalassemia patients there were 8 class I,
and 5 class II patients. Busulfan, ﬂudarabine, and rabbit ATG
were mainly used as myeloablative conditioning regimen.
Cyclosporine and short-course methotrexate were mainly
used as graft-versus-host disease (GvHD) prophylaxis in BMT
group, while cyclosporine alone was used in CBT group.
CD34+ cell doses per kilogram body weight recipients were
ranged from 5.6 to 34.7x106 (median 11.3x106) in BMT group
(n¼9), and from 1.6 to 3x105 (median 2.3x105) in CBT group
(n¼4). Complete donor engraftments were achieved in 11
patients. Mixed-chimerism states with donor predominance
were present in 2 patients from BMT and 1 patient from CBT
group. No patients experienced graft failure. Neutrophil re-
coveries were evident on days +10 to +23 (median day +14),
and platelet recoveries were observed on days +19 to +64
(median day +40). 2 patients had mild veno-occlusive dis-
eases and were later completely reversible. No patients
developed acute or chronic GvHD. Therewere no mortalities.
1 patient had treatable pneumocystis pneumonia at 4
months post CBT. Median follow-up time for all patients was
2 years (1 month to 4 years 8 months). Overall (OS) and
disease-free survival (DFS) were 100% and 100% for all pa-
tients (n¼14). Based on risk class, the OS and DFS for class I
thalassemia patients (n¼9) were 100% and 100%, and class II
patients (n¼4) were 100% and 100%, respectively.
Conclusions: Our experiences in HCT for thalassemias and
hemoglobinopathies were very favorable. Regular follow-up
visits are encouraged to determine long term outcomes.396
Engraftment and Immune Recovery (IR) in Good Risk
Patients Undergoing Hematopoietic Stem Cell
Transplantation (HSCT): Comparison of Two Different
Approaches Using Cyclophosphamide (CY) for T-Cell
Tolerization
John L. Wagner 1, Dolores Grosso 1, Onder Alpdogan 1,
Matthew Carabasi 1, Joanne Filicko 2, Margaret Kasner 3,
Ubaldo Martinez 1, Mark Weiss 1, Neal Flomenberg 1.
1 Department of Medical Oncology, Kimmel Cancer Center,
Thomas Jefferson University, Philadelphia, PA; 2 Thomas
Jefferson University Hospital, Philadelphia, PA; 3Medical
Oncology, Thomas jefferson University, Philadelphia, PA
We developed a 2 step haploidentical HSCT where 76 pa-
tients received myeloablative or reduced intensity regimens
followed by a DLI containing a ﬁxed dose of 2.0 x 108/kg T
cells (HSCT step 1). After 2 days, 60mg/kg/d x 2 of CY was
infused, followed a day later by a CD34 selected PBSC product
[HSCT step 2 median dose 5 x 106/kg (range 1.64-10)]. We
concurrently used a 1 step HSCT approach in a group of 16
patients, 8 with unrelated donors (URD) and 8 patients (6
with haploidentical, 2 with matched related donors) with
comorbidities precluding eligibility for the 2 step protocol.
The 1 step patients were given the same conditioning, but
afterwards received unmanipulated PBSC’s [median CD 34
dose 7.18x106/kg, (range 4.41-10); median T cell dose 2.9 x
108/kg, (range 1.4-3.90)]. CY 60mg/kg/d x 2 was infused 48
